Next Article in Journal / Special Issue
Efficient Computational Design of a Scaffold for Cartilage Cell Regeneration
Previous Article in Journal
Musculoskeletal Model Development of the Elbow Joint with an Experimental Evaluation
Previous Article in Special Issue
Biocatalyst Screening with a Twist: Application of Oxygen Sensors Integrated in Microchannels for Screening Whole Cell Biocatalyst Variants
Article Menu
Issue 2 (June) cover image

Export Article

Open AccessReview
Bioengineering 2018, 5(2), 32; https://doi.org/10.3390/bioengineering5020032

Role of Bioreactor Technology in Tissue Engineering for Clinical Use and Therapeutic Target Design

1
Institute for Liver and Digestive Health, Division of Medicine, Faculty of Medical Sciences, University College London, Royal Free Hospital Campus, Rowland Hill Street, Hampstead, London NW3 2PF, UK
2
Department of Nanotechnology, Division of Surgery & Interventional Science, Faculty of Medical Sciences, University College London, London NW3 2QG, UK
*
Author to whom correspondence should be addressed.
Received: 2 March 2018 / Revised: 17 April 2018 / Accepted: 18 April 2018 / Published: 24 April 2018
(This article belongs to the Special Issue Advances in Micro-Bioreactor Design for Organ Cell Studies)
Full-Text   |   PDF [225 KB, uploaded 3 May 2018]   |  

Abstract

Micro and small bioreactors are well described for use in bioprocess development in pre-production manufacture, using ultra-scale down and microfluidic methodology. However, the use of bioreactors to understand normal and pathophysiology by definition must be very different, and the constraints of the physiological environment influence such bioreactor design. This review considers the key elements necessary to enable bioreactors to address three main areas associated with biological systems. All entail recreation of the in vivo cell niche as faithfully as possible, so that they may be used to study molecular and cellular changes in normal physiology, with a view to creating tissue-engineered grafts for clinical use; understanding the pathophysiology of disease at the molecular level; defining possible therapeutic targets; and enabling appropriate pharmaceutical testing on a truly representative organoid, thus enabling better drug design, and simultaneously creating the potential to reduce the numbers of animals in research. The premise explored is that not only cellular signalling cues, but also mechano-transduction from mechanical cues, play an important role. View Full-Text
Keywords: mechanotransduction; tissue engineering; cell signaling; in vitro model; bioreactor mechanotransduction; tissue engineering; cell signaling; in vitro model; bioreactor
Figures

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Selden, C.; Fuller, B. Role of Bioreactor Technology in Tissue Engineering for Clinical Use and Therapeutic Target Design. Bioengineering 2018, 5, 32.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Bioengineering EISSN 2306-5354 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top